Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.

• Status: Terminated
• Trial end date: 2019-09-15
• Target enrollment: 0
• Participant gender: All

Summary

To estimate distribution's parameters of 18F-Flutemetamol (Vizamyl®) fixation on myocardium for patients with amyloid cardiac injuries.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Toulouse
• Treatments: Flutemetamol

Criteria

Inclusion Criteria:

• Patients followed for amyloidosis with proved cardiac injury or strongly suspected:

• cardiac echography with typical signs of amyloid injury,

• anatomical result confirming presence of amyloid deposits at cardiac or peripheral level

• Signature of Informed Consent Form,

• Affiliation to a social security system

Exclusion Criteria:

• Patient who suffers from another pathology which could lead cardiac injury (coronary disease, valvular disease, other pathology of deposit),

• Pregnancy and lactating women,

• Absence of effective contraception,

• Irradiating examination performed within the last 12 months or scheduled within the next 12 months,

• Unable patient physically, mentally or legally to provide informed consent,

• Patient under a system of legal protection